Blueprint Medicines ROE - Return on Equity 2014-2024 | BPMC

Blueprint Medicines return on equity for the quarter ending September 30, 2024 was -47.63.

  • Blueprint Medicines average return on equity for 2023 was -141.14, a 87.91% decline from 2022.
  • Blueprint Medicines average return on equity for 2022 was -75.11, a 889.59% increase from 2021.
  • Blueprint Medicines average return on equity for 2021 was -7.59, a 50.39% increase from 2020.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.

Blueprint Medicines ROE - Return on Equity 2014-2024 | BPMC

  • Blueprint Medicines average return on equity for 2023 was -141.14, a 87.91% decline from 2022.
  • Blueprint Medicines average return on equity for 2022 was -75.11, a 889.59% increase from 2021.
  • Blueprint Medicines average return on equity for 2021 was -7.59, a 50.39% increase from 2020.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.